Andelyn Biosciences

Andelyn Biosciences is a full-service cell and gene therapy Contract Development and Manufacturing Organisation (CDMO) dedicated to accelerating the development and production of innovative therapies to deliver more treatments to more patients.

Originating from Nationwide Children's Hospital's pioneering gene therapy research, Andelyn Biosciences has evolved into a trusted partner in the biotechnology sector. With over two decades of experience, the company has produced more than 450 Good Manufacturing Practice (GMP) batches of viral vector therapies, contributing to numerous clinical trials and the approval of a gene therapy product. Andelyn's commitment to scientific excellence, collaborative partnerships, and reliable manufacturing positions it at the forefront of the industry, anticipating and shaping the future of gene therapy.

Key Products and Services:

Viral Vector Manufacturing: Specialising in the production of viral vectors, Andelyn offers scalable solutions from preclinical stages to commercial manufacturing, ensuring high-quality outputs for gene therapy applications.

Plasmid Manufacturing: Providing both research-grade and GMP plasmid production, the company supports various gene therapy and vaccine development programmes with precision and compliance.

Process Development: Andelyn's experts assist in developing, optimising, and scaling processes tailored to client-specific needs, enhancing efficiency and efficacy in therapeutic production.

Laboratory Services: Offering comprehensive analytical development and quality control testing, Andelyn ensures the integrity and safety of gene therapy products through rigorous evaluation.

Technology Transfer: Facilitating seamless transitions from research to manufacturing, the company ensures that processes are efficiently and accurately transferred to meet regulatory and production standards.

AAV Curator™ Platform: A data-driven, programme-specific platform designed to optimise adeno-associated virus (AAV) vector development, reducing costs and accelerating timelines for gene therapy programmes.

Beyond its technical capabilities, Andelyn Biosciences is deeply invested in community engagement and education. The company actively participates in service initiatives, educational outreach, and partnerships aimed at promoting public health and scientific literacy. This dedication reflects Andelyn's holistic approach to advancing healthcare and its mission of 'Turning Hope Into Reality™'.

With state-of-the-art facilities and a team of seasoned professionals, Andelyn Biosciences continues to lead the charge in transforming scientific discoveries into tangible, life-changing therapies for patients worldwide.